Abstract | BACKGROUND: HYPOTHESIS: METHODS: Sixty-two patients with PH were enrolled and initiated with neubulizedlow-dose iloprost (2.5 µg per inhalation, 6× daily) for 24 weeks in 13 medical centers in China. Efficacy endpoints included changes in 6-minute walk distance (6MWD), World Health Organization functional class (WHO-FC), and hemodynamic parameters. RESULTS: Fourteen patients (22.6%) prematurely discontinued the study: 8 due to clinical worsening (6 in WHO-FCIII-IV at baseline), 4 because of protocol change, and 2 patients lost during follow-up. In the remaining 48 patients, 6MWD was increased from 356 ± 98 meters to 414 ± 99 meters (P < 0.001) and WHO-FC improved significantly (P = 0.006) after 24-week inhalation therapy. Cardiac output, cardiac index, and mixed venous oxygen saturation improved significantly compared with baseline (n = 34, P < 0.05). Most of the hemodynamic parameters improved significantly in patients in WHO-FC II (P < 0.05) but not in patients in WHO-FCIII-IV. CONCLUSIONS: Low-dose iloprost inhalation significantly improved exercise capacity and functional status in patients with PH. It was well tolerated. The improvement of hemodynamics was confirmed in patients with WHO-FCI-II but not in patients with WHO-FCIII-IV, suggesting the importance of early treatment in patients with advanced disease stages.
|
Authors | Yun-Juan Sun, Chang-Ming Xiong, Guang-Liang Shan, Qing Gu, Wei-Jie Zeng, Xian-Ling Lu, Feng Zhu, Zhi-Hong Liu, Xin-Hai Ni, Jian-Guo He, Iloprost Therapy on Pulmonary Hypertension Study Group |
Journal | Clinical cardiology
(Clin Cardiol)
Vol. 35
Issue 6
Pg. 365-70
(Jun 2012)
ISSN: 1932-8737 [Electronic] United States |
PMID | 22488211
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | © 2012 Wiley Periodicals, Inc. |
Chemical References |
|
Topics |
- Administration, Inhalation
- Adult
- China
- Exercise Tolerance
(drug effects)
- Female
- Health Status Indicators
- Heart Rate
- Hemodynamics
(drug effects)
- Humans
- Hypertension, Pulmonary
(drug therapy, pathology)
- Iloprost
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Oxygen Consumption
- Prospective Studies
- Statistics as Topic
- Time Factors
- Treatment Outcome
|